Healthcare

Boston Scientific Corporation(BSX-PA)

Live Price

Offline

$122.18

+2.37% today

1Y Change

—

Window

No data

Market Cap: $175.45B
Revenue Growth: +19.9%
EPS Growth: +55.6%
Dividend Yield: 0.0%

No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Boston Scientific Corporation (BSX-PA) is a Healthcare stock with a market cap of $175.45B. The stock last traded around $122.18. Baseline metrics include revenue growth of +19.9%, EPS growth of +55.6%, a dividend yield of 0.0%. What stands out right now is revenue +19.9%, EPS +55.6%, free cash flow +38.3% with operating margin 20.1% and ROIC 9.9%. Valuation sits in the middle of the pack at P/E 23.4 and price/sales 4.0. Stock Foundry combines BSX-PA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+19.9% vs +7.6% peer median

Operating Margin

Near sector median

+20.1% vs +19.4% peer median

P/E

Below sector median

23.4 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2023 was reported on Sep 30, 2023, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +19.9% and EPS at +55.6%, with operating margin around 20.1%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

BSX-PA

—

Normalized return

SPY

—

S&P 500

Excess Return

—

Relative to SPY

BSX-PA Max Drawdown

—

Trailing 1Y

SPY Max Drawdown

—

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for BSX-PA and SPY.

Calendar-year return history is still loading or unavailable.

Company Overview

Boston Scientific Corporation

Last Updated: May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E: 23.4
EV/EBITDA: 19.5
Price/Sales: 4.0
Price/Book: 3.2

Growth

Revenue: +19.9%
EPS: +55.6%
Free Cash Flow: +38.3%

Profitability

Gross Margin: 70.4%
Operating Margin: 20.1%
Net Margin: 17.2%
ROE: 14.8%
ROIC: 9.9%

Balance Sheet

Debt/Equity: 0.43
Current Ratio: 1.90

Earnings Reports

📅 Last reportedSep 30, 2023

Period	B/M	EPS	EPS Δ	Revenue	Rev Δ
— Sep 30, 23		0.34 Est —	—	3527000.0B Est —	—
— Jun 30, 23		0.19 Est —	—	3599000.0B Est —	—
— Mar 31, 23		0.22 Est —	—	3389000.0B Est —	—
— Dec 31, 22		0.10 Est —	—	3242000.0B Est —	—
— Sep 30, 22		0.13 Est —	—	3170000.0B Est —	—
— Dec 31, 21		0.07 Est —	—	3127000.0B Est —	—
— Sep 30, 21		0.29 Est —	—	2932000.0B Est —	—
— Jun 30, 21		0.13 Est —	—	3077000.0B Est —	—
— Mar 31, 21		0.24 Est —	—	2752000.0B Est —	—
— Dec 31, 20		0.15 Est —	—	2709000.0B Est —	—
— Sep 30, 20		-0.11 Est —	—	2659000.0B Est —	—
— Jul 29, 20	✓	0.08 Est 0.02	+420.2%	2003000.0B Est 1136500.0B	+76.2%
— Apr 29, 20	✗	0.28 Est 0.31	-9.7%	2543000.0B Est 2789096.8B	-8.8%
— Feb 5, 20	✓	0.46 Est 0.44	+4.5%	2904000.0B Est 2772000.0B	+4.8%
— Oct 23, 19	✓	0.39 Est 0.38	+2.6%	2707000.0B Est 2635763.2B	+2.7%
— Jul 24, 19	✓	0.39 Est 0.38	+2.6%	2631000.0B Est 2561763.2B	+2.7%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official

No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guide Read how to compare stocks